Form 4: Esperion Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 2,234 shares of common stock on December 17, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On December 17, 2024, Eric Warren, the Chief Commercial Officer of Esperion Therapeutics, Inc., sold 2,234 shares of the company's common stock.
- The shares were sold at a price of $2.429 per share.
- This transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
- Following the sale, Warren directly owns 160,121 shares of Esperion Therapeutics.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.
Industry Context
Insider sales are a common occurrence, especially to cover tax obligations related to equity compensation. The market typically views these sales in the context of the overall insider ownership and company performance.
Stakeholder Impact
- The sale may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of execution of the Limited Power of Attorney. |
| December 17, 2024 | Date of the stock sale transaction. |
| December 18, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.